Search

Your search keyword '"Mašić, Dženan"' showing total 25 results
Start Over Author "Mašić, Dženan"
25 results on '"Mašić, Dženan"'

1. Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial

Author

Mašić, Dženan, Stengaard-Pedersen, Kristian, Løgstrup, Brian Bridal, Hørslev-Petersen, Kim, Hetland, Merete Lund, Junker, Peter, Østergaard, Mikkel, Ammitzbøll, Christian, Möller, Sören, Christensen, Robin, and Ellingsen, Torkell

Published
2021
Full Text
View/download PDF

2. Plasma levels of multiple cardiovascular- and inflammation-related proteins analysed for associations with disease activity and anti-cyclic citrullinated peptide status in active early rheumatoid arthritis

Author

Mašić, Dženan, primary, Stengaard-Pedersen, Kristian, additional, Bridal Løgstrup, Brian, additional, Hørslev-Petersen, Kim, additional, Hetland, Merete Lund, additional, Junker, Peter, additional, Østergaard, Mikkel, additional, Nielsen, Claus Henrik, additional, Kruhøffer, Mogens, additional, Bøgebjerg, Mathias Emil, additional, Röttger, Richard, additional, Christensen, Robin, additional, and Ellingsen, Torkell, additional

Published
2022
Full Text
View/download PDF

3. Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate:secondary analyses from the randomised controlled OPERA trial

Author

Mašić, Dženan, Stengaard-Pedersen, Kristian, Løgstrup, Brian Bridal, Hørslev-Petersen, Kim, Hetland, Merete Lund, Junker, Peter, Østergaard, Mikkel, Ammitzbøll, Christian, Möller, Sören, Christensen, Robin, Ellingsen, Torkell, Mašić, Dženan, Stengaard-Pedersen, Kristian, Løgstrup, Brian Bridal, Hørslev-Petersen, Kim, Hetland, Merete Lund, Junker, Peter, Østergaard, Mikkel, Ammitzbøll, Christian, Möller, Sören, Christensen, Robin, and Ellingsen, Torkell

Abstract

To compare changes in low-density lipoprotein cholesterol and other lipids in patients with rheumatoid arthritis (RA) randomised to a 1-year treat-to-target strategy with either adalimumab plus methotrexate or placebo plus methotrexate. Prespecified secondary analyses from the OPERA trial, where 180 early and treatment-naïve RA patients received methotrexate 20 mg once weekly in combination with either placebo or subcutaneous adalimumab 40 mg every other week. Serum lipid levels were measured at baseline and after 1 year. Changes in lipid levels were analysed using mixed linear models based on the intention-to-treat (ITT) population. Overall, 174 patients were included in the ITT population (adalimumab plus methotrexate n = 86; placebo plus methotrexate n = 88). Differences between changes in lipid levels were low-density lipoprotein cholesterol 0.18 mmol/l [95% CI − 0.05 to 0.42], total cholesterol 0.27 mmol/l [− 0.002 to 0.54], high-density lipoprotein cholesterol 0.05 mmol/l [− 0.06 to 0.15], triglycerides 0.11 mmol/l [− 0.08 to 0.29], very-low-density lipoprotein cholesterol 0.03 mmol/l [− 0.05 to 0.12], and non-high-density lipoprotein cholesterol 0.22 mmol/l [− 0.02 to 0.46]. In early RA patients treated to tight control of inflammation over a period of 1 year with either adalimumab plus methotrexate or placebo plus methotrexate, changes in lipid levels were similar. Trial registration number: NCT00660647.

Published
2021

4. Sjögrens syndrom

Author

Voss, Anne, Heller Asmussen, Karsten, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Johannsen, Finn Elkjær

Published
2018

5. Vaskulit

Author

Laustrup, Helle, Faurschou, Mikkel, Baslund, Bo, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

6. Idiopatiske inflammatoriske myopatier

Author

Diederichsen, L., Søren Jacobsen, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

7. Reumatoid artrit

Author

Hauge, Ellen-Margrethe, Hetland, Merete Lund, Hørslev-Petersen, Kim, Østergaard, Mikkel, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Johannsen, Finn Elkjær

Published
2018

8. Patient med smerter i ét led

Author

Dzenan Masic, Finn Elkjær Johannsen, claus manniche, anne voss, Ellen-Margrethe Hauge, Voss, Anne, Manniche, Claus, Masic, Dzenan, Hauge, Ellen-Margrethe, Elkjær Johannsen, Finn, and Mašić, Dženan

Published
2018

9. Farmakologisk smertebehandling

Author

Mogens Pfeiffer Jensen, claus manniche, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

11. Patient med bløddelsessmerter

Author

Finn Elkjær Johannsen, claus manniche, Dzenan Masic, Ellen-Margrethe Hauge, anne voss, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, Elkjær Johannsen, Finn, and Masic, Dzenan

Published
2018

12. Postinfektiøs artrit

Author

Hauge, Ellen-Margrethe, Voss, Anne, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

13. Krystalartritter

Author

Larsen, Kasper Søltoft, Skøt Hindrup, Jens, Slot, Ole, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

14. Systemisk lupus erythematosus

Author

Voss, A., Mikkel Faurschou, Søren Jacobsen, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

15. Psoriasisartrit

Author

Munk, Heidi Lausten, Deleuran, Mette Søndergaard, Deleuran, Bent, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

17. Hereditære bindevævssygdomme

Author

Tarp, Ulrik, Harboe Nygaard, Rie, Frederiksen, Anja Lisbeth, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

19. Koagulationssygdomme

Author

Poulsen, Lone Hvitfeldt, Voss, Anne, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

20. Regionale smertetilstande og idrætsmedicin

Author

Elkjær Johannsen, Finn, Fredberg, Ulrich, Olesen, Jens Lykkegaard, Kjær, Michael, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2018

21. Glukokortikoidinjektion i led, slimsække, seneskeder og bløddele

Author

Ulrich Fredberg, Bent Deleuran, Kristian Stengaard-Pedersen, Pødenphant, Jan, Jacobsen, Søren, Manniche, Claus, Stengaard-Pedersen, Kristian, Tarp, Ulrik, Voss, Anne, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

Published
2006

22. Patient med smerter i flere led

Author

Ellen-Margrethe Hauge, anne voss, Finn Elkjær Johannsen, claus manniche, Dzenan Masic, Voss, Anne, Manniche, Claus, Masic, Dzenan, Hauge, Ellen-Margrethe, Elkjær Johannsen, Finn, and Mašić, Dženan

23. Patient med rygsmerter

Author

claus manniche, Ellen-Margrethe Hauge, anne voss, Dzenan Masic, Finn Elkjær Johannsen, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, Elkjær Johannsen, Finn, and Masic, Dzenan

Subjects
spinal pain, Low Back Pain
Abstract

Baggrund 50 % af den voksne befolkning oplever hvert år smerter i nakke, lænd, torakale afsnit eller måske i flere af ryggens regioner samtidigt. Rygsymptomer er altså et særdeles hyppigt fænomen, som i hovedparten af tilfældene er af uspecifik oprindelse, og som i de fleste tilfælde har ganske god prognose. Hos 10-20% af patienterne fortsætter smerterne imidlertid i måneder eller år trods relevante behandlingsforsøg. Udredning af såvel akutte (varighed < 3 mdr.) som kroniske (varighed > 3 mdr.) tilstande foregår gennem en diagnostisk triage: • Først afklares det, om der er red flags til stede, som kræver hurtig indsats. • Herefter vurderes om smerterne skyldes mulige specifikke diagnoser. • Er patienten i restgruppen, foretages en bredere udredning for at afdække eventuelle behandlingsmuligheder og prognose. Væsentlige kliniske karakteristika RED FLAGS Enhver førstegangsudredning af patienten med rygsmerter indledes ved klinisk at udpege de få alvorlige diagnoser, som kræver akut eller hurtig indsats: Sphinctersymptomer eller abnorme sensibilitets-/refleksforhold af perineum giver mistanke om cauda equina-syndrom. Progredierende parese af over- eller underekstremiteter eller paralyse er ofte tegn på truende incarceration af nerverod. L’Hermittes tegn, bilaterale UE-symptomer, hyperrefleksi eller Babinskis tåfænomen. Tænk begyndende medullært tværsnitssyndrom. Almensymptomer med fx vægttab, træthed og feber, tidligere cancersygdom, +50 år. Tænk andre red flags som infektion, systemsygdom eller cancer. Background Every year, 50% of the adult population experiences pain in the neck, low back pain, thoracic pain. Low Back pain is a very frequent phenomenon, which in most cases is of non-specific origin and which in most cases has a good prognosis. However, in 10-20% of patients, the pain persists for months or years despite relevant treatment trials. Both acute (duration 3 months) conditions are investigated through a diagnostic triage: • First, it is clarified whether red flags are present that require prompt action. • Thereafter, we assess whether the pain is due to possible specific diagnoses. • If the patient is in the residual group, a broader assessment is made to identify any treatment options and prognosis. Essential clinical characteristics RED FLAGS Any initial assessment of the patient with back pain is initiated by clinically identifying the few serious diagnoses that require urgent or urgent action: Sphincter symptoms or abnormal sensitivity / reflex conditions of the perineum cause cauda equina syndrome. Progressive palsy of upper or lower extremities or paralysis is often indicative of threatening nerve root incarceration. L’Hermitte’s signs, bilateral UE symptoms, hyper-reflex or Babinski’s toe phenomenon. Think incipient medullary cross-sectional syndrome. Common symptoms with eg weight loss, fatigue and fever, previous cancer disease, +50 years. Think of other red flags like infection, system disease or cancer.

24. Non-farmakologisk behandling og rehabilitering

Author

Berit Schiøttz-Christensen, Finn Elkjær Johannsen, Kirstine Amris, Eva Ejlersen Wæhrens, Lone Donbæk Jensen, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Elkjær Johannsen, Finn

25. Plasma levels of multiple cardiovascular- and inflammation-related proteins analysed for associations with disease activity and anti-cyclic citrullinated peptide status in active early rheumatoid arthritis.

Author

Mašić D, Stengaard-Pedersen K, Bridal Løgstrup B, Hørslev-Petersen K, Hetland ML, Junker P, Østergaard M, Nielsen CH, Kruhøffer M, Bøgebjerg ME, Röttger R, Christensen R, and Ellingsen T

Subjects
Humans, Anti-Citrullinated Protein Antibodies, Interleukin-2, Autoantibodies, Inflammation, Peptides, Cyclic, E-Selectin, Arthritis, Rheumatoid diagnosis
Abstract

Objectives: To compare plasma levels of 92 cardiovascular- and inflammation-related proteins (CIRPs) and to analyse for associations with anti-cyclic citrullinated peptide (anti-CCP) status and disease activity in early and treatment-naive rheumatoid arthritis (RA)., Methods: Olink CVD-III-panel was used to measure 92 CIRP plasma levels in 180 early, treatment-naive, and highly inflamed RA patients from the OPERA trial. CIRP plasma levels as well as correlation between CIRP plasma levels and RA disease activity were compared between anti-CCP groups. CIRP level-based hierarchical cluster analysis was performed in each anti-CCP group separately., Results: The study included 117 anti-CCP-positive and 63 anti-CCP-negative RA patients. Among the 92 CIRPs measured, the levels of chitotriosidase-1 (CHIT1) and tyrosine-protein-phosphatase non-receptor-type substrate-1 (SHPS-1) were increased and those of metalloproteinase inhibitor-4 (TIMP-4) decreased in the anti-CCP-negative group compared to anti-CCP-positive group. The strongest associations with RA disease activity were found for interleukin-2 receptor-subunit-alpha (IL2-RA) and E-selectin levels in the anti-CCP-negative group and for C-C-motif chemokine-16 levels (CCL16) in the anti-CCP-positive group. None of the differences passed the Hochberg sequential multiplicity test, however, the CIPRs were interacting and thus the prerequisites of the Hochberg procedure were not fulfilled. CIRP level-based cluster analysis identified two patient clusters in both anti-CCP groups. Demographic and clinical characteristics were similar in the two clusters for each anti-CCP group., Conclusions: In active and early RA, the findings regarding CHIT1, SHPS-1 TIMP-4, IL2-RA, E-selectin, and CCL16 differed between the two anti-CCP groups. In addition, we identified two patient clusters that were independent of the anti-CCP status.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results